News and Announcements
Optiscan Imaging – CEO Interview
- Published October 17, 2012 12:54PM UTC
- Publisher Wholesale Investor
- Categories Executive Interviews
Optiscan is a global leader in the development and application of miniaturised microscopic imaging technologies for medical markets. Optiscan’s imaging technology allows live cellular imaging for earlier and better detection of pre-cancerous and cancerous lesions and more accurate resection during surgery. Optiscan’s technology has been incorporated into Pentax endoscopes since 2006 and will soon be incorporated into the product offering of Carl Zeiss Meditec in neurosurgery and ENT surgery.
Executive Interviews
Following the Billions: Where the Hyperscalers are Betting on the Future
The roadmap for the next decade isn’t hidden in pitch decks—it’s written on the balance sheets of Microsoft, Amazon, and Google. Their collective investment is flowing into three key areas: GPU Chips, AI Factories, and Energy. This foundational buildout signals a $7–$20 trillion economic convergence, where the physical race for infrastructure and energy is paramount. The article also covers the powerful macro case for digital assets in this new era.
The Great Re-Allocation: Why AI is Forcing Smart Money From Software to Hard Science
Smart money is rapidly shifting its investment focus from commoditized software to hard science and deep tech, as AI dissolves traditional software moats. Discover the dual pressure on investors and the pivot to businesses with durable, real-world defensive barriers.
AI is The Cheapest, Highest-Leverage Investment You Will Ever Make
AI tools offer a 10x productivity increase for a minimal monthly cost, making them the highest-ROI investment in business today. However, this massive potential remains dormant. The real opportunity is not in owning the tools, but in having the strategic playbook to deploy them organization-wide and build a defensible competitive advantage.
Backed By Leading Investment Groups and Family Offices
